ReviewClinical pharmacokinetics2000
Methods for clinical monitoring of cyclosporin in transplant patients.
Review in Clinical pharmacokinetics, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.Clinical pharmacokinetics · 2007Pooled it
- Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.European journal of clinical pharmacology · 2012Trial
- Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients.Clinical pharmacokinetics · 2004Trial
- Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.Clinical pharmacokinetics · 2002Trial
- Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants.Clinical pharmacokinetics · 2002Trial
- Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.Therapeutic drug monitoring · 2015Article
- Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II.Clinical pharmacokinetics · 2009Review
- Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.Clinical pharmacokinetics · 2009Review
- Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients.Clinical pharmacokinetics · 2006Article
- Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients.British journal of clinical pharmacology · 2005Article
- Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.Clinical pharmacokinetics · 2004Review
- Cyclosporin therapeutic drug monitoring--an established service revisited.The Clinical biochemist. Reviews · 2003Article
- Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation.European journal of clinical pharmacology · 2003Article
- Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations.Clinical pharmacokinetics · 2002Review
- Review
- Limited sampling strategies.Clinical pharmacokinetics · 2000Review
- Risks and complications associated with dental implant failure: Critical update.National journal of maxillofacial surgeryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclosporin was introduced into clinical practice in the early 1980s and has since been shown to prolong survival for transplant recipients. Because cyclosporin is a narrow therapeutic index drug and there are significant consequences associated with 'subtherapeutic' and 'supratherapeutic' concentrations, cyclosporin therapy is monitored as part of routine patient follow-up. However, the optimal method for the therapeutic drug monitoring of cyclosporin has yet to be defined. Currently, the most common method involves monitoring pre-dose trough concentrations, but this method is less than ideal. Other methods of monitoring cyclosporin therapy include monitoring the area under the concentration-time curve, limited sampling strategies, monitoring of single concentrations other than troughs and pharmacodynamic monitoring. Bayesian forecasting has been used successfully in clinical practice with other drugs with narrow therapeutic indices. However, few studies are available regarding Bayesian forecasting and cyclosporin. Existing studies are preliminary in nature and involve the old Sandimmun formulation rather than the Neoral formulation. Although these methods show promise, they have not gained widespread acceptance. This is because of their impracticality and the lack of prospective studies comparing other monitoring methods with trough concentration monitoring. Further comparative studies evaluating the impact of the specific monitoring method on definite patient outcomes are warranted.
Indexed as
Identifiers
10843461What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.